Hemostemix (CVE:HEM) Trading 30% Higher – Should You Buy?

Shares of Hemostemix Inc. (CVE:HEM) traded up 30% during mid-day trading on Tuesday . The company traded as high as C$0.15 and last traded at C$0.13. Approximately 430,289 shares were traded during trading, a decline of 10% from the average daily volume of 480,285 shares. The stock had previously closed at C$0.10.

Hemostemix Trading Up 30.0%

The company’s 50-day moving average is C$0.10 and its 200 day moving average is C$0.14. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market cap of C$18.94 million, a PE ratio of -3.79 and a beta of 0.20.

Insider Buying and Selling at Hemostemix

In other Hemostemix news, Director Peter Alan Lacey acquired 200,000 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was purchased at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. Company insiders own 10.43% of the company’s stock.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.